"10.1371_journal.pone.0076398","plos one","2013-10-16T00:00:00Z","Rita Finley; Shiona K Glass-Kaastra; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly","Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Guelph, Ontario, Canada; Division of Medical Microbiology, Island Medical Program, University of British Columbia, Victoria, British Columbia, Canada; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; Department of Infectious Diseases and Microbiology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Québec, Canada; Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Synder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada","Analyzed the data: SKGK. Wrote the paper: SKGK RF. Project conception: RF JC. Data acquisition: RF JC. Interpretation of results: RF SKGK JC JH DP KW. Supervision: RF. Manuscript revision: JH DP KW JC SKGK RF.","KW has received research funds and/or has been on the advisory board from Abbott, Bayer, Gilead, Merck, Pfizer, Optimer Pharma, Roche, Vertex. JC has received honoraria from the Canadian Agency for Drugs and Technologies in Health for work as an expert reviewer and clinical expert, respectively, for projects on the role of rapid PCR testing for MRSA in hospitalized patients and the use of vancomycin or metronidazole for treatment of Clostridium difficile colitis within the last three years. He has also received speakers honoraria related to new anti-bacterial agents from Janssen-Ortho and Pfizer within the past three years. He has received financial support for research activities from the Alberta Heritage Foundation for Medical Research, the Canadian Institutes for Health Research, PHAC, NCCID, Alberta Advanced Education and Technology, and Pfizer. RF, SGK, DP and JH do not have any competing interests. This does not alter the authors adherence to all the PLOS ONE policies on sharing data or materials.","2013","10","Rita Finley","RF",6,TRUE,NA,NA,1,2,TRUE,FALSE,FALSE,0,NA,FALSE
